Skip to main content
. 2023 Jul 6;14:1106968. doi: 10.3389/fendo.2023.1106968

Table 1.

Comparison of general data between the normoglycemic group and T2DM group.

normoglycemic T2DM p
Participants 621 622
Age 49.61 ± 6.79 50.41 ± 8.79 0.07
Male/Female 307/314 328/294 0.25
BMI (kg/m2) 24.69 ± 3.26 25.68 ± 2.59* <0.05
WC (cm) 85.57 ± 9.89 89.07 ± 8.39* <0.05
HC (cm) 96.98 ± 6.57 98.77 ± 7.52* <0.05
WHR 0.88 ± 0.07 0.90 ± 0.05* <0.05
SBP (mm/Hg) 124.34 ± 17.40 124.59 ± 12.38 0.77
DBP (mm/Hg) 80.49 ± 10.69 80.20 ± 7.78 0.58
TC (mmol/L) 5.06 ± 1.02 5.25 ± 1.12* <0.05
TG (mmol/L) 1.88 ± 1.63 2.49 ± 2.58* <0.05
HDL-C (mmol/L) 1.39 ± 0.36 1.23 ± 0.30* <0.05
LDL-C (mmol/L) 3.12 ± 0.86 3.04 ± 0.90 0.12
FPG (mmol/L) 5.30 (5.00,5.60) 8.07 (7.27,9.41)* <0.05
OGTT2hPG (mmol/L) 6.60 (5.70,7.80) 12.45 (10.40,14.70)* <0.05
HbA1c (%) 5.70 ± 0.45 8.25 ± 0.93* <0.05
FINS (pmol/L) 15.11 (11.48,20.14) 10.92 (7.34,16.30)* <0.05
OGTT2hINS (pmol/L) 60.11 (38.02,92.02) 31.39 (20.74,44.23)* <0.05
HOMA-β 172.92 (125.72,229.69) 48.43 (28.45,72.87)* <0.05
HOMA-IR 3.59 (2.62,4.85) 3.94 (2.56,6.12)* <0.05
TSH (mIU/L) 1.97 (1.35,2.90) 2.20 (1.43,3.31)* <0.05
FT3 (pmol/L) 4.89 ± 0.97 5.30 ± 0.64* <0.05
FT4 (pmol/L) 16.07 ± 2.60 17.78 ± 2.44* <0.05
TFQI -0.16 (-0.30,0.00) 0.08 (-0.12,0.26)* <0.05

BMI, body mass index; WC, waist circumference; HC, hip circumference; WHR, waist-hip ratio; SBP/DBP, systolic/diastolic blood pressure; TC, total cholesterol; TG, triglycerides; HDL-C/LDL-C, high-density/low-density lipoprotein cholesterol; FPG, fasting blood glucose; OGTT2hPG, 2h intravenous plasma glucose; HbA1c, glycosylated hemoglobin; FINS, fasting insulin; OGTT2hINS, 2h intravenous plasma insulin; HOMA-β, Homeostasis model assessment of islet β function index; HOMA-IR, Homeostasis model assessment of insulin resistance;TSH, thyroid-stimulating hormone; FT3, free triiodothyronine; FT4, free thyroxine;TFQI, thyroid feedback quantile index.*Compared to the normoglycemic P<0.05.

Bold values: Compared to the normoglycemic P<0.05.